secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0000950170-24-116848
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes Q3 2024: proprietary net sales up 18% YoY to $273M; GAAP EPS $0.56
---------------------------------------------------------------------------

- Total revenues $378.1M vs $380.9M YoY; proprietary net sales $273M (+18% YoY).
- LYBALVI sales $74.7M (+47%), VIVITROL $113.7M (+14%), ARISTADA $84.7M.
- GAAP net income from continuing ops $92.8M, diluted EPS $0.56; non-GAAP net income $121.4M.
- Cash & investments $927.8M; repurchased 4.4M shares for $115.6M in Q3; $200M remaining under buyback.
- Company reiterates 2024 financial expectations; advancing ALKS 2680 phase 2 studies in narcolepsy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000095017024116848/0000950170-24-116848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000095017024116848/alks-20241024.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-116848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer